Hong Kong-based Ally Bridge Capital Partners and China-focused WI Harper provided $10 million in Series B funding for U.S.-based onco-immunotherapy biotech Cold Genesys in a deal that builds on a $13.8 million Series A from the same investors a year ago. The funds are for a pivotal trial of oncology candidate CG0070 aimed at creating an immune response against cancer cells. Ally Bridge is also in focus in China as part of a management-led buyout of WuXi PharmaTech ($WX), offering $46 per share, which values the company at $3 billion. A special committee of board members is now evaluating the proposed deal. In July, the firm also launched a new Asian healthcare hedge fund, Ally Bridge LB Healthcare Fund, with an eye for opportunities created by Chinese reforms since 2007, according to Bloomberg. Frank Yu, former Och-Ziff Capital Management Group head of China investments, started the venture. Information about the size of the fund was not available. Release